HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pradimicin-IRD

polycyclic antibiotic produced by the actinobacteria Amycolatopsis sp.

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bauermeister, Anelize: 2 articles (10/2019 - 06/2019)
2.	Almeida, Larissa Costa de: 1 article (10/2019)
3.	Costa-Lotufo, Leticia Veras: 1 article (10/2019)
4.	Machado-Neto, João Agostinho: 1 article (10/2019)
5.	Moraes, Luiz Alberto Beraldo de: 1 article (10/2019)
6.	Rezende-Teixeira, Paula: 1 article (10/2019)
7.	Santos, Evelyne Alves Dos: 1 article (10/2019)
8.	Almeida, Larissa C: 1 article (06/2019)
9.	Calil, Felipe A: 1 article (06/2019)
10.	Costa-Lotufo, Letícia V: 1 article (06/2019)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2019 - "The cellular and molecular mechanism of action of pradimicin-IRD was then investigated in the colorectal cancer cell line HCT 116. "
2.	Neoplasms (Cancer) 10/01/2019 - "While all tested colon cancer cells were sensitive to pradimicin-IRD treatment with IC50 in micromolar range, non-tumor fibroblasts were significantly less sensitive (p < 0.05). "
3.	Melanoma (Melanoma, Malignant) 06/01/2019 - "Pradimicin-IRD displayed potential antimicrobial activity against Streptococcus agalactiae (MIC 3.1 μg/mL), Pseudomonas aeruginosa (MIC 3.1 μg/mL) and Staphylococcus aureus (MIC 3.1 μg/mL), and also cytotoxicity against tumour and non-tumour cell lines with IC50 values ranging from 0.8 μM in HCT-116 colon carcinoma cells to 2.7 μM in MM 200 melanoma cells. "
4.	Colonic Neoplasms (Colon Cancer) 10/01/2019 - "While all tested colon cancer cells were sensitive to pradimicin-IRD treatment with IC50 in micromolar range, non-tumor fibroblasts were significantly less sensitive (p < 0.05). " 10/01/2019 - "Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells."
5.	Carcinoma (Carcinomatosis) 06/01/2019 - "Pradimicin-IRD displayed potential antimicrobial activity against Streptococcus agalactiae (MIC 3.1 μg/mL), Pseudomonas aeruginosa (MIC 3.1 μg/mL) and Staphylococcus aureus (MIC 3.1 μg/mL), and also cytotoxicity against tumour and non-tumour cell lines with IC50 values ranging from 0.8 μM in HCT-116 colon carcinoma cells to 2.7 μM in MM 200 melanoma cells. "

Related Drugs and Biologics

1.	Antineoplastic Agents (Antineoplastics)